Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Blog

  • Home
  •  
  • Blog



  • Most Read
  • Latest Comments
  • Blog
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Blog
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Blog
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Blog
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Blog
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • Apiam eyes first viral vaccine production in 12 months from new facility
    • News

    Apiam eyes first viral vaccine production in 12 months from new facility

    Despite having only received a $700k government grant to build a much needed viral vaccine facility, Apiam Animal Health (ASX: AHX) is already eyeing production within the next 12 months, potentially including one for Japanese Encephalitis which is currently impacting the Australian’s pig industry. While the state-of-the-art facility is not expected to be fully completed

    Read More
    Public
  • PointsBet inks landmark sportsbetting partnership in Canada to accelerate growth, eh
    • News

    PointsBet inks landmark sportsbetting partnership in Canada to accelerate growth, eh

    Since accepting their first bet within just 50 seconds of their launch in Canada, sportsbetting company PointsBet (ASX: PBH) has set out to make a huge nationwide push across the country having partnered with Maple Leaf Sports & Entertainment in what has to be classified as a landmark deal. Unlike other partnerships PointsBet has made

    Read More
    Public
  • Bigger fish: ResApp to be acquired by pharma giant Pfizer
    • News

    Bigger fish: ResApp to be acquired by pharma giant Pfizer

    It’s not a question of AstraZeneca or Pfizer for digital health company ResApp Health (ASX: RAP) who have today entered into a binding scheme implementation deed to be acquired by pharmaceutical giant, Pfizer. Yes, one of the world’s biggest pharma companies has been perusing the ASX for a small homegrown biotech to snap up, we’re

    Read More
    Public
  • High Court sides with AFT Pharmaceuticals after Nurofen maker dispute
    • News

    High Court sides with AFT Pharmaceuticals after Nurofen maker dispute

    Sticks and stones may break my bones but words may result in legal action because they can be misconstrued despite conscious wording.  Luckily for AFT Pharmaceuticals (ASX: AFP) the Australian High Court has sided with them, dismissing complaints made by the makers of Nurofen, Reckitt-Benckiser around the advertising of AFT’s painkiller product, Maxigesic.  Just yesterday

    Read More
    Public
  • K2 shares Fly as Maptek acquires strategic stake verging on takeover territory
    • News

    K2 shares Fly as Maptek acquires strategic stake verging on takeover territory

    The Australian landscape is dominated by extensive miners all over the continent, so making sure that their operations and reporting run smoothly becomes a vital part of their existence. K2fly (ASX: K2F) steps into this scene as a leading provider of platform-based SaaS cloud solutions to some of the largest miners, including Rio Tinto, Fortescue

    Read More
    Public
  • Ardent Leisure Group set to cash in on US arcades business and turn focus to theme parks
    • News

    Ardent Leisure Group set to cash in on US arcades business and turn focus to theme parks

    After several years of M&A interest in their US arcades business, Ardent Leisure Group (ASX: ALG) is set to offload their Main Event business to US operator Dave & Buster’s for USD $835 million on a cash and debt free basis.  The Group, alongside co-owner RedBird Capital Partners, is selling retail entertainment business Main Event

    Read More
    Public
  • «
  • ‹
  • 390
  • 391
  • 392
  • 393
  • 394
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.